Poly-L-lactic acid

The Pharmaceutical Benefits Scheme subsidises poly-L-lactic acid for patients with severe facial lipoatrophy.

For patients with severe facial lipoatrophy caused by therapy for human immunodeficiency virus (HIV) infection, treatment with poly-L-lactic acid (Sculptra®) can be subsidised through the Pharmaceutical Benefit Scheme (PBS) under section 85 of the National Health Act 1953.

Restriction details

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing poly-L-lactic acid (Sculptra®).

Schedule item details

All applications for treatment for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection must be made by an accredited injector who has received administration training by Sanofi-Aventis. Patients must be referred from the HIV physician to the accredited injector.


Poly-L-lactic acid is available in single vials containing 150 mg powder for injection.

Initial treatment

Initial treatment is limited to a maximum quantity of 2 vials and 4 repeats.

Maintenance treatment

Maintenance treatment is limited to 1 re-treatment, maximum quantity of 2 vials every 2 years.

Patient eligibility

Patients must meet the relevant criteria as indicated in the restrictions and be eligible to receive Pharmaceutical Benefits Scheme subsidised medicines.

Lodging an application

All applications for treatment for eligible patients, by approved injectors, may be obtained by contacting us on the Complex Drug Enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 27 January 2016

This information was printed Thursday 17 August 2017 from humanservices.gov.au/health-professionals/enablers/poly-l-lactic-acid It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.